Publication Name	World Journal of Gastroenterology
Manuscript ID	5525
Country	China

Received	2013-09-13 08:22
Peer-Review Started	2013-09-13 12:11
To Make the First Decision	2013-09-27 16:31
Return for Revision	2013-09-30 11:51
Revised	2013-10-18 23:52
Second Decision	2014-03-05 14:16
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-03-05 15:21
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-03-27 20:51
Typeset the Manuscript	2014-04-19 16:27
Publish the Manuscript Online	2014-05-07 10:10

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin’s lymphoma
Manuscript Source	Invited Manuscript
All Author List	Wei-Ping Liu, Wen Zheng, Yu-Qin Song, Ling-Yan Ping, Gui-Qiang Wang and Jun Zhu
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China 81241073 Peking University Cancer Hospital Foundation for Scientific Research 2013-Autonomous-9
Corresponding Author	Jun Zhu, MD, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. zhu-jun@bjcancer.org
Key Words	Hepatitis B surface antigen; Seroconversion; Non-Hodgkin’s lymphoma; Rituximab; Entecavir
Core Tip	We describe the case of a 68-year-old hepatitis B surface antigen (HBsAg)-positive male patient who received rituximab-based immunochemotherapy for follicular lymphoma, and experienced hepatitis B virus (HBV) reactivation following cessation of lamivudine prophylaxis. Subsequent entecavir treatment produced rapid, sustained viral suppression and HBsAg seroconversion. Lamivudine prevents HBV reactivation but resistance rates may be as high as 17% in lymphoma patients. Available data suggest that entecavir is effective and safe for the treatment of HBV reactivation in lymphoma patients. Prophylactic antiviral therapy is recommended for patients with active or occult HBV infection following chemotherapy or immunochemotherapy. Potent antiviral drugs with a high genetic barrier to resistance should be considered in these cases.
Publish Date	2014-05-07 10:10
Citation	Liu WP, Zheng W, Song YQ, Ping LY, Wang GQ, Zhu J. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin’s lymphoma. World J Gastroenterol 2014; 20(17): 5165-5170
URL	http://www.wjgnet.com/1007-9327/full/v20/i17/5165.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i17.5165

Full Article (PDF)	WJG-20-5165.pdf
Full Article (Word)	WJG-20-5165.doc
Manuscript File	5525-Review.doc
Answering Reviewers	5525-Answering reviewers.pdf
Copyright License Agreement	5525-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Ethics_Committee_20130912131859.PDF
Non-Native Speakers of English Editing Certificate	5525-Language certificate.pdf
Peer-review Report	5525-Peer review(s).pdf
Scientific Editor Work List	5525-Scientific editor work list.doc